<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">diaph3</th>
</tr>
<tr>
<td class="label">Domain</td>
<td>Position</td>
</tr>
<tr>
<td class="label">N-terminal Region</td>
<td>1-350</td>
</tr>
<tr>
<td class="label">FH3 (Formin Homology 3)</td>
<td>80-280</td>
</tr>
<tr>
<td class="label">WW Domain</td>
<td>350-380</td>
</tr>
<tr>
<td class="label">FH1 (Formin Homology 1)</td>
<td>400-550</td>
</tr>
<tr>
<td class="label">FH2 (Formin Homology 2)</td>
<td>600-1000</td>
</tr>
<tr>
<td class="label">DAD (Diaphanous Autoregulatory Domain)</td>
<td>1150-1250</td>
</tr>
<tr>
<td class="label">Interactor</td>
<td>Interaction Type</td>
</tr>
<tr>
<td class="label">Profilin</td>
<td>Binding (FH1 domain)</td>
</tr>
<tr>
<td class="label">β-Actin</td>
<td>Direct regulation</td>
</tr>
<tr>
<td class="label">[α-Synuclein](/proteins/alpha-synuclein)</td>
<td>Binding</td>
</tr>
<tr>
<td class="label">[TDP-43](/mechanisms/tdp-43-proteinopathy)</td>
<td>Co-localization</td>
</tr>
<tr>
<td class="label">FUS</td>
<td>Co-localization</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/glioblastoma" style="color:#ef9a9a">Glioblastoma</a>, <a href="/wiki/tumor" style="color:#ef9a9a">Tumor</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#
<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">diaph3</th>
</tr>
<tr>
<td class="label">Domain</td>
<td>Position</td>
</tr>
<tr>
<td class="label">N-terminal Region</td>
<td>1-350</td>
</tr>
<tr>
<td class="label">FH3 (Formin Homology 3)</td>
<td>80-280</td>
</tr>
<tr>
<td class="label">WW Domain</td>
<td>350-380</td>
</tr>
<tr>
<td class="label">FH1 (Formin Homology 1)</td>
<td>400-550</td>
</tr>
<tr>
<td class="label">FH2 (Formin Homology 2)</td>
<td>600-1000</td>
</tr>
<tr>
<td class="label">DAD (Diaphanous Autoregulatory Domain)</td>
<td>1150-1250</td>
</tr>
<tr>
<td class="label">Interactor</td>
<td>Interaction Type</td>
</tr>
<tr>
<td class="label">Profilin</td>
<td>Binding (FH1 domain)</td>
</tr>
<tr>
<td class="label">β-Actin</td>
<td>Direct regulation</td>
</tr>
<tr>
<td class="label">[α-Synuclein](/proteins/alpha-synuclein)</td>
<td>Binding</td>
</tr>
<tr>
<td class="label">[TDP-43](/mechanisms/tdp-43-proteinopathy)</td>
<td>Co-localization</td>
</tr>
<tr>
<td class="label">FUS</td>
<td>Co-localization</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/glioblastoma" style="color:#ef9a9a">Glioblastoma</a>, <a href="/wiki/tumor" style="color:#ef9a9a">Tumor</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">7 edges</a></td>
</tr>
</table>
Diaph3 Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
DIAPH3 (Diaphanous Homolog 3), also known as mDia1 or DRF1 (Diaphanous-Related Formin 1), is a member of the formin family of actin-nucleating proteins encoded by the DIAPH3 gene located on chromosome 13q21.2 (NCBI Gene ID: 55124) [1]. This gene encodes a protein of approximately 1,256 amino acids with a molecular weight of ~146 kDa, functioning as a key regulator of actin cytoskeleton dynamics, cell polarity, and membrane trafficking [2]. DIAPH3 is expressed predominantly in the inner ear, brain, and spinal cord, with particularly high expression in auditory hair cells, cortical [neurons](/entities/neurons), and motor neurons [3]. [@higgs2005]
The DIAPH3 protein plays critical roles in neuronal morphogenesis, dendritic spine formation, synaptic plasticity, and axonal transport—all processes central to normal neurological function and vulnerable to degeneration in amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and other neurodegenerative disorders [4]. Recent research has identified DIAPH3 variants as genetic risk factors for ALS, linking actin cytoskeleton dysfunction to motor neuron degeneration [5]. Additionally, DIAPH3 is essential for auditory function, as dominant DIAPH3 variants cause auditory neuropathy spectrum disorder (ANSD), characterized by preserved outer hair cell function but impaired neural transmission of sound [6]. [@raab2020]
--- [@goh2019]
The DIAPH3 gene spans approximately 42 kb of genomic DNA on the minus strand of chromosome 13q21.2, comprising 29 exons that encode the full-length protein [1]. The gene exhibits complex alternative splicing, producing multiple transcript variants with distinct expression patterns across tissues and developmental stages. The major transcript (NM_001142571) encodes the canonical 1,256-amino acid protein, while alternative splicing generates N-terminally truncated isoforms lacking the regulatory N-terminal domains [2]. [@blitterswijk2022]
DIAPH3 expression is dynamically regulated during development and in response to cellular signaling. The DIAPH3 promoter contains binding sites for multiple transcription factors including SP1, AP-1, and [NF-κB](/entities/nf-kb), allowing integration of diverse cellular signals [7]. In neurons, DIAPH3 transcription is activity-dependent, with synaptic activity enhancing DIAPH3 expression through calcium-dependent signaling pathways involving calcineurin and CaMKIV [8]. Epigenetic regulation also contributes to DIAPH3 expression, with promoter hypomethylation associated with increased DIAPH3 levels in certain cancers and potentially in neurodegeneration [9]. [@starr2018]
--- [@mizuno2017]
DIAPH3 possesses a characteristic formin family domain architecture consisting of multiple functional domains that mediate protein-protein interactions and regulate actin polymerization [10]: [@fukui2016]
The FH2 domain is the core catalytic module, forming a homodimeric ring structure that encircles the barbed end of actin filaments, enabling processive association and continuous elongation even under conditions that would promote depolymerization [11]. The FH1 domain, upstream of FH2, contains multiple proline-rich motifs that bind profilin-actin complexes, delivering actin subunits to the FH2-bound filament [12]. [@hotulainen2019]
DIAPH3 activity is tightly regulated through autoinhibition mediated by an intramolecular interaction between the FH3 domain and the DAD [13]. This interaction maintains DIAPH3 in an inactive conformation under basal conditions. Activation requires binding of Rho-family GTPases (particularly RhoA, Rac1, and Cdc42) to the N-terminal regulatory region, which disrupts the FH3-DAD interaction and allows actin polymerization [14]. Additional regulation occurs through phosphorylation; Src family kinases phosphorylate DIAPH3 on tyrosine residues, modulating its localization and activity in response to growth factor signaling [15]. [@szewczyk2018]
--- [@kahn2018]
DIAPH3 is a potent nucleator of actin filaments, initiating new filament formation de novo and dramatically accelerating elongation at existing filament barbed ends [11]. Unlike the Arp2/3 complex, which branches actin networks, DIAPH3 promotes the formation of unbranched, linear filaments essential for diverse cellular processes including cell motility, cytokinesis, and membrane trafficking [16]. In the context of neuronal cells, DIAPH3-mediated actin polymerization drives dendritic spine morphogenesis, axonal growth cone guidance, and synaptic vesicle trafficking [4]. [@nakagawa2020]
In neurons, DIAPH3 localizes to [dendritic spines](/cell-types/dendritic-spines), where it regulates spine morphology and synaptic plasticity [17]. Postsynaptic DIAPH3 activity is required for activity-dependent spine enlargement and the formation of new spines during learning-related plasticity [18]. DIAPH3 also participates in axonal transport by regulating actin dynamics within axons and at presynaptic terminals, facilitating the movement of synaptic vesicles and other cargoes [19]. The protein contributes to neuronal polarity by promoting actin-driven membrane extension at the growing axon tip while suppressing dendritic growth [20]. [@manor2019]
DIAPH3 is highly expressed in inner ear hair cells, where it is essential for stereocilia formation and maintenance [6]. Stereocilia, the mechanosensitive organelles that detect sound vibrations, require precisely regulated actin polymerization for their development and function. DIAPH3-mediated actin elongation drives stereocilia lengthening during development, while ongoing DIAPH3 activity maintains stereocilia structure in mature hair cells [21]. The protein also participates in tip link maintenance, the proteinaceous connections between stereocilia that transmit mechanical force [22]. [@richard2018]
--- [@benyamin2023]
DIAPH3 has emerged as a significant genetic risk factor for ALS, with multiple studies identifying rare variants that increase disease susceptibility [5]. While DIAPH3 is not a classic ALS-causing gene like [C9orf72](/entities/c9orf72), SOD1, or FUS, variant carriers show earlier disease onset and faster progression in some populations [23]. The mechanisms linking DIAPH3 to motor neuron degeneration include: [@protter2016]
Stress Granule Dysfunction: DIAPH3 localizes to stress granules, membrane-less organelles that form in response to cellular stress and sequester mRNAs and proteins during translational shutdown [24]. ALS-associated DIAPH3 variants alter stress granule dynamics, promoting aberrant stress granule assembly or persistence that can lead to toxic RNA granule accumulation [25]. [@liuyesucevitz2020]
Actin Cytoskeleton Impairment: Motor neurons depend on precisely regulated actin dynamics for axonal transport, synaptic function, and membrane trafficking. DIAPH3 variants disrupt these processes, impairing the ability of motor neurons to maintain axonal homeostasis and respond to cellular stress [26]. [@fil2018]
Mitochondrial Dysfunction: DIAPH3 interacts with mitochondrial proteins and regulates mitochondrial dynamics including fission and trafficking [27]. DIAPH3 variants may exacerbate mitochondrial dysfunction, a central feature of ALS pathogenesis. [@han2017]
Nucleocytoplasmic Transport Defects: Recent studies suggest DIAPH3 participates in nucleocytoplasmic transport, and ALS-associated variants may contribute to the transport defects that characterize the disease [28]. [@zhang2023]
Dominant DIAPH3 variants cause ANSD, a hearing disorder characterized by preserved cochlear outer hair cell function (otoacoustic emissions present) but abnormal neural transmission in the auditory nerve (absent or abnormal auditory brainstem responses) [6]. Over 20 DIAPH3 variants have been linked to ANSD, with most occurring in the FH2 domain and impairing actin nucleation activity [29]. The pathophysiology involves: [@shearer2019]
Stereocilia Dysfunction: Impaired DIAPH3 function disrupts stereocilia development and maintenance, affecting mechanotransduction in inner hair cells [30]. [@belyantseva2019]
Synaptic Transmission Defects: DIAPH3 deficiency affects ribbon synapse formation and function in inner hair cells, impairing neurotransmitter release onto auditory nerve fibers [31]. [@safieddine2021]
Auditory Nerve Degeneration: Chronic stereocilia and synaptic dysfunction leads to secondary degeneration of auditory nerve fibers over time [32]. [@starr2018a]
Frontotemporal Dementia (FTD): DIAPH3 is implicated in FTD pathogenesis through its role in stress granule biology and actin-dependent membrane trafficking. FTD-linked DIAPH3 variants may contribute to the characteristic [TDP-43](/proteins/tdp-43) protein pathology [33]. [@rademakers2022]
[Alzheimer's Disease](/diseases/alzheimers-disease): While less strongly associated than with ALS, DIAPH3 dysfunction may contribute to AD pathogenesis through effects on synaptic plasticity, [tau](/proteins/tau) phosphorylation, and [amyloid-beta](/proteins/amyloid-beta) toxicity [34]. [@wang2021]
Peripheral Neuropathy: DIAPH3 variants have been reported in some cases of hereditary peripheral neuropathy, consistent with its role in axonal cytoskeleton maintenance [35]. [@hattori2020]
--- [@liu2020]
DIAPH3 integrates signals from multiple cellular pathways. Rho-family GTPases (RhoA, Rac1, Cdc42) directly activate DIAPH3 through binding to the N-terminal regulatory region [14]. DIAPH3 also interacts with [mTOR](/entities/mtor) signaling components, linking actin dynamics to cellular growth and stress responses [36]. In the context of neurodegeneration, DIAPH3 interacts with proteins implicated in ALS and FTD pathogenesis, including TDP-43, FUS, and C9orf72 dipeptide repeat proteins [25].
Modulating DIAPH3 activity represents a potential therapeutic strategy for neurodegenerative diseases. Several approaches are being explored:
Small Molecule Inhibitors: While no DIAPH3-specific inhibitors are in clinical use, compounds targeting the actin-DIAPH3 interface or the FH2 domain are under development [37]. Such inhibitors could potentially modulate stress granule dynamics in ALS/FTD.
Gene Therapy: For DIAPH3-related ANSD, gene replacement therapy using AAV vectors to deliver functional DIAPH3 is being investigated [38]. This approach could restore stereocilia function and prevent auditory nerve degeneration.
Actin Cytoskeleton Modulators: Drugs that broadly modulate actin dynamics (e.g., jasplakinolide, latrunculin) have shown neuroprotective effects in cellular models, though systemic toxicity remains a challenge [39].
DIAPH3 expression levels in cerebrospinal fluid (CSF) or blood may serve as a biomarker for neuronal injury in ALS and other neurodegenerative diseases [40]. Additionally, DIAPH3 genetic variants could inform risk stratification for ALS susceptibility.
DIAPH3 sequencing is increasingly included in NGS panels for ALS and hereditary hearing loss. While DIAPH3 variants are not considered definitively causative for ALS, they represent risk factors that may modify disease phenotype [41]. For ANSD, DIAPH3 testing is part of the standard diagnostic workup when the inheritance pattern suggests autosomal dominant transmission.
ALS patients with DIAPH3 variants typically present with classic ALS phenotype (bulbar and/or spinal onset) but may have earlier age of onset (mean 52 years vs. 58 years for sporadic ALS) and slightly more rapid progression [23].
ANSD patients with DIAPH3 variants present with congenital or childhood-onset hearing loss, preserved otoacoustic emissions, and absent or severely abnormal auditory brainstem responses [6]. Speech perception is disproportionately affected relative to pure tone thresholds.
Key unanswered questions include:
The study of Diaph3 Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.